Needle

ImmuneChip+

Advancing multi-organ tissue chips

OVERVIEW

The program aims to enhance validated tissue models by adding immune system capability, incorporating tissue sensors, and automating the manufacturing process with the goal to position new 3D tissue models that faithfully recapitulate components of the human body as an integral part of the drug development process.

PARTNERS

Companies we have partnered with on this program to date

APPROACH

Rapid advances in tissue chip technologies now make the prospect of commercialization more realistic.

The ImmuneChip+ program aims to address key remaining challenges, including:
  • Automated manufacturing
  • Incorporation of sensors for long-term tissue monitoring
  • Integration of multiple human tissue types anchored by an immune system model

Program Goals

ambulance
Biosensors

Successful integration of two biosensors for near-continuous monitoring of the developing tissues.

check list
Immune System Monitoring

Demonstration of spatiotemporal control over integrated immune system components.

healing hand
Automated Manufacturing

Production of at least 25 platforms within 24 hours.

Needle

ImmuneChip+

Funding
Opened

6/30/21

Amendment

#13

Get PDF

Paused

8/25/21

angle down

Amendment

#14

Get PDF

Program
Closes

finish line flag

Program Faq

Is the ImmuneChip+ program open to academics or do only companies qualify?

It is open to both academia and industries as long as the respondents meet all the requirements described in the EZ-BAA and the special instructions.

Can large companies apply to the ImmuneChip+ program?

Any entity can submit proposal via the EZ-BAA portal as long as they are registered with www.SAM.gov.

Can companies/universities outside of the United States apply for ImmuneChip+ funding?

Yes. Applicants from outside of the United States are eligible to apply for funding.

Do academic institutions also need to provide a 30% cost share?

Yes. Abstract submissions should include a cost-share that is within our target range of minimum 30-50% minimum, unless you satisfy the regulatory exception (included below for reference). Currently, none of the DRIVe partners under the DRIVe EZ-BAA have been awarded a contract that does not include a cost-share component below range, including all universities and non-profit organizations. Cost-share may be in-kind or cash contributions. It may also come from a third-party investor/sponsor, however, it is up to you to ensure you receive their contribution toward the proposed project. Many organizations offer to cover Overhead or Fringe Benefits. Some also offer pro-bono labor hours or sponsored equipment, materials, or subcontractor costs. A combination of all of the above could be acceptable. It would need to be indicated on a submission what is being cost-shared. To qualify for no cost-share under an EZ-BAA award, a respondent must show that there is "no probability that the respondent will receive present or future benefits from participation as described in Federal Acquisition Regulation (FAR) 16.303." Examples of present or future benefits include increased technical know-how, training for employees, acquisition of goods or services, development of a commercially viable product that can be sold in the commercial market, and use of background knowledge in future contracts.

What are the data sharing requirements of this program?

Projects funded under this program have data sharing requirements with the U.S. government consistent with government regulation (FAR 52.227-14 Rights in Data). The program requires that you share all data (including raw data) generated under the project for government use consistent with the regulation.

The EZ-BAA application is so short. Can I include links to figures or references?

While you can include links to figures or references, it is not mandated that reviewers view that outside information. At this time, the abstract format does not accept any figures, only text.

ImmuneChip+ is paused